Skip to main
  1. Stocks
  2. Eli Lilly
  3. Forecast
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 45%
Buy 50%
Hold 0%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is supported by dominant momentum in its incretin franchise, with Mounjaro sales up 65% to $10.72B and Zepbound up 49% to $5.35B in 3Q26, while the company also raised guidance by $5bn, signaling that demand is still underpenetrated and volume-led. Its growth case is strengthened by expanding access through the Medicare GLP-1 Bridge, rising international share, and a broadening portfolio that includes Foundayo, which generated $184M in 3Q26 and could become a meaningful new driver as diabetes and international launches progress. Beyond obesity, the pipeline adds further upside through oncology, immunology, and neuroscience, with retatrutide, Kisunla, and upcoming 2027 readouts offering multiple catalysts that could sustain revenue and EPS growth despite pricing pressure.

Bears say

Eli Lilly is vulnerable to a downside case in which obesity growth deteriorates faster than expected as pricing and competition intensify, pressuring operating margins, slowing EPS growth, and driving P/E compression to 21x. The company’s aggressive manufacturing expansion has helped, but supply constraints and allocation choices that favor higher-margin markets have intensified scrutiny over access, especially for lower-income patients and Medicare pricing. Key risks include weaker sales of Mounjaro, Zepbound, and Foundayo in US and international markets, underwhelming recent launches, possible quality or manufacturing issues, and disappointing capital deployment, even as Foundayo’s oral formulation could help by 2027-28.

Eli Lilly (LLY) has been analyzed by 22 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Eli Lilly (LLY) Analyst Forecast & Price Prediction

Get the latest Eli Lilly (LLY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Eli Lilly (LLY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 22 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,443.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,443.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Eli Lilly (LLY) Analyst Forecast & Price Prediction

Get the latest Eli Lilly (LLY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Eli Lilly (LLY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LLY stock data and trends